1. Paratek Pharmaceuticals. Paratek announces FDA approval of NUZYRA™ (omadacycline) (media release). 2 Oct 2018.
2. Paratek Pharmaceuticals. Paratek announces acceptance of European Marketing Authorization application for oral and intravenous omadacycline (media release). 4 Oct 2018.
3. Huband MD, Pfaller MA, Streit JM, et al. Omadacycline in vitro activity against skin and skin structure, respiratory, and urinary tract pathogens collected from the U.S. and Europe during the SENTRY Surveillance Program (2017). (abstract no. 627 plus poster). In: ASM Microbe 2018. 2018.
4. Stapert L, Wolfe C, Shinabarger D, et al. In vitro activities of omadacycline and comparators against anaerobic bacteria. Antimicrob Agents Chemother. 2018;62(4):e00047–118.
5. Paratek Pharmaceuticals. Nuzyra (omadacycline): US prescribing information. 2018.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf
. Accessed 23 Oct 2018.